i
n
f
l
a
r
x
Loading
Loading
izicopan
Oral C5aR inhibitor
Phase 2b planning ongoing
Additional renal indications such as aHUS, IgAN, C3G, and others
Topline Phase 2a reported
Additional indications in immuno-dermatology, hematology, neurology and others
Vilobelimab
C5a inhibitor
Approved by European Commission*
Phase 2 "Just Breathe" ASPR/BARDA clinical platform study
Vilobelimab
C5a inhibitor
Phase 3 reported**
IFX002
C5a inhibitor
For optimized use in chronic inflammatory indications
*Commercial partnering and distribution options in the EU being considered.
** Phase 3 stopped early for futility at interim analysis, FDA interaction considered.